Akiskal HS. (1981). “Subaffective disorders:dysthymic, cyclothymic and bipolar II disorders in the "borderline" realm.”. Psychiatr Clin North Am4: 25-46. PMID7232236.
Sar V,Akyuz G,kugu N et al (2006). “Axis I Dissociative Disorder Comorbidity in BorderlinePersonality disorder and Reports of Childhood Trauma.”. Journal of Clinical Psychiatry67: 1583-1590. PMID17107251.
Marmer SS, Fink D. (1994). “Rethinking the comparison of borderline personality disorder and multiple personality disorder.”. Psychiatr Clin North Am17: 743-771. PMID7877901.
Trinka E, Kienpointner G, Unterberger I, et al (2006). “Psychiatric comorbidity in juvenile myoclonic epilepsy”. Epilepsia47: 2086-2091. PMID17201708.
Hirschfeld,R.M (1997). “Pharmacotherapy of borderline personality disorder”. Journal of Clinical Psychiatry58 (suppl 14): 48-52. PMID9418746.
Steinberg,B.J.,Trestman,R.,Mitropoulou,V.,Serby,M.,Silverman,J.,Coccaro,E.,Weston,S.,De Vegvar,M.,&Siever,L.J. (1997). “Depressive response to physostigmine challenge in borderline personality disorder patients.”. Neuropsychopharmacology17 (4): 264-273. PMID9326751.
Coccaro,E.F. (1998). “Clinical outcome of psychopharmacologic treatment of borderline and schizotypal personality disorder subjects.”. Journal of Clinical Psychiatry59 (1). PMID9448667.
Schmahl.D.J. (2006). “Neural correlates of antinociception in borderline personality disorder”. Arch Gen Psychiatry.63: 659-667. PMID16754839.
Soloff PH and Milward JW (1983). “Developmental Histories of Borderline Patients.”. comprehensive Psychiatry24: 574-588. PMID6653098.
Gunderson JG,Kerr J,Englund DW (1980). “The Families of borderlines : A Comparative Study.”. Archuves of General Psychiatry37: 27 - 33. PMID7352837.
Zweig-Frank H and Paris J (1991). “Parents'Emotional Neglect and Overprotection according to the Recollection of Patients with borderline Parsonarty Disorder.”. American Journal of Psychiatry148: 648-651. PMID2018169.
Spinhoven P, Giesen-Bloo J, van Dyck R, Arntz A. (2008). “Can assessors and therapists predict the outcome of long-term psychotherapy in borderline personality disorder?”. J Clin Psychol64 (6): 667-686. PMID18384120.
Simpson,E.B.,Pistorello,J.,et al (1998-05). “Use of Dialectical behavior therapy in a partial hospitsl program for women with borderline personality disorder”. Psychiatric Services49 (5): 669-673. PMID9603574.
Bateman,A.,Fonagy,P. (1999-10). “The effectiveness of partial hosipitalization in the treatment ob BPD:A randomized controlled trial.”. Am J Psychiatry156: 1563-1569. PMID10518167.
Vita A, De Peri L, Sacchetti E. (2011-10). “Antipsychotics, antidepressants, anticonvulsants, and placebo on the symptom dimensions of borderline personality disorder: a meta-analysis of randomized controlled and open-label trials.”. J Clin Psychopharmacol31 (5): 613-24. PMID21869691.
Paris,J (2002). “Implications of long-term outcome research for management of with borderline personality disorder.”. Harv Rev Psychiatry10: 315-323. PMID12485978.
Paris,j.,Zweig-Frank,H. (2001). “A 27-year follow-up of patients with borderline personality disorder”. Compr Psychiatry42 (6): 482-7. PMID11704940.
Bridget F. Grant et al. (2008-04). “Prevalence, Correlates, Disability, and Comorbidity of DSM-IV Borderline Personality Disorder: Results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions,Lifetime Prevalence and Odds Ratios of DSM-IV Borderline Personality Disorder and Sociodemographic Characteristics and Sex”. J Clin Psychiatry69 (4): 533-545. PMID18426259.
1990年代からアメリカのマサチューセッツ州にあるマクリーン・ホスピタル（英語版）で Maclean Study for Adult Development と呼ばれる多大な費用を投じた大規模なBPD研究が行われており、現在も続けられている。この長期予後はその研究の中からの報告である。（藤内栄太 (2010)）
